WebJul 1, 2024 · The initial conversion price represents a premium of 30.0% over the last reported sale price of $39.29 per share of Cytokinetics’ common stock on June 30, … WebMar 31, 2024 · On Friday 03/31/2024 the closing price of the Cytokinetics Inc share was $35.19 on NAS. Compared to the opening price on Friday 03/31/2024 on NAS of $35.02, this is a gain of 0.48%.
Analysts Have Conflicting Sentiments on These Healthcare …
WebGenerating Revenue. 4. Later Stage VC. 02-Mar-2011. $1M. $3.3M. Completed. Generating Revenue. To view Cytonics’s complete valuation and funding history, request access ». WebCYTK - Cytokinetics Inc Stock quote - CNNMoney.com Markets Tech Media Success Video Cytokinetics Inc (NASDAQ:CYTK) Real-Time Quotes 35.31 BATS BZX Real … pvmmy
Cytonics Company Profile: Valuation & Investors PitchBook
WebCytokinetics, Incorporated CYTK: Raising target price to $38.00 CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $38.000000; an Industry Subrating of … Find the latest Cytokinetics, Incorporated (CYTK) stock discussion in Yahoo … See the company profile for Cytokinetics, Incorporated (CYTK) including business … View the basic CYTK option chain and compare options of Cytokinetics, … NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. Visitors trend … NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. Visitors trend … At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio … Find out all the key statistics for Cytokinetics, Incorporated (CYTK), … Get the detailed quarterly/annual income statement for Cytokinetics, Incorporated … Find out the direct holders, institutional holders and mutual fund holders for … See Cytokinetics, Incorporated (CYTK) Environment, Social and Governance … WebFeb 28, 2024 · In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $1.18 per share for CYTK, compared to a broader Zacks Consensus Estimate of a loss of $1.22 per share. WebSep 23, 2024 · SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo ... pvman lol